California, Texas, and Florida have enacted new regulations that remove the requirement for an in-person medical visit before prescribing GLP-1 medications through telehealth platforms. The rule changes, which took effect between February 15 and March 1, affect more than 90 million residents across the three states and are expected to significantly expand access to weight management treatment.
The moves come as telehealth-based prescribing of GLP-1 drugs has grown into a major access point for patients. Companies like Ro, Hims & Hers, Calibrate, and Found now account for an estimated 20-25% of all new GLP-1 prescriptions in the United States, according to data from IQVIA [1].
What Changed in Each State
California's Medical Board updated its prescribing guidelines on February 15 to allow initial GLP-1 prescriptions via audio-video telehealth encounters without a prior in-person visit. Previously, California required at least one in-person evaluation before a controlled substance or high-cost injectable could be prescribed through telehealth. GLP-1 medications are not controlled substances, but the state's prior rules grouped them with other medications that required an initial office visit [2].
Texas enacted House Bill 2847, signed by Governor Greg Abbott on January 30, which went into effect on March 1. The bill specifically addresses anti-obesity medications, allowing prescribers to initiate treatment through telehealth if the patient provides recent lab work (within 90 days) and agrees to follow-up monitoring at specified intervals. Texas had been one of the more restrictive states for telehealth prescribing, requiring an in-person visit for any new prescription exceeding $500 per month [3].
Florida's Board of Medicine adopted a rule change on February 20, effective immediately, that creates a new category for "chronic disease management medications" that can be prescribed via telehealth without prior in-person contact. GLP-1 receptor agonists for both weight management and diabetes are included in this category. Florida's previous rule was ambiguous, with some practitioners interpreting it as requiring in-person visits and others not [4].
Why These Changes Matter
Geographic access to obesity medicine specialists is severely limited in the United States. The American Board of Obesity Medicine has certified approximately 7,500 physicians nationwide, a number that is wholly inadequate to treat the more than 100 million Americans with obesity [5]. Many rural areas and smaller cities have no obesity medicine specialists at all.
Telehealth fills this gap. A patient in rural East Texas or California's Central Valley can now connect with a board-certified obesity medicine physician through a video visit, receive a prescription, and have their medication shipped to their door or sent to a local pharmacy.
Dr. Angela Fitch, president of the Obesity Medicine Association, has advocated for expanded telehealth prescribing. "Obesity is a chronic disease that requires ongoing management, similar to hypertension or diabetes," Dr. Fitch said. "We don't require in-person visits for every blood pressure medication refill. Applying that same standard to anti-obesity medications is sensible and overdue."
Safety Guardrails
The new rules include safety provisions designed to ensure telehealth prescribing is done responsibly.
All three states require audio-video encounters, not audio-only phone calls, for initial GLP-1 prescriptions. The prescriber must verify the patient's identity and conduct a medical evaluation that includes reviewing medical history, current medications, and recent lab work.
California and Florida require that prescribers document a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, consistent with FDA-approved indications. Texas requires recent lab results including fasting glucose, HbA1c, lipid panel, and thyroid function before initiating treatment.
All three states mandate follow-up evaluations at least every 90 days during the first year of treatment and at least every 6 months thereafter. These follow-ups can also be conducted via telehealth.
Dr. Robert Pearl, former CEO of Kaiser Permanente's medical group and a professor at Stanford Medical School, supports the guardrails but cautioned that enforcement will determine their effectiveness. "Regulations are only as good as their enforcement mechanisms," he said. "The state medical boards will need to monitor telehealth prescribers to ensure they're conducting proper evaluations, not just rubber-stamping prescriptions."
Impact on Telehealth Companies
The regulatory changes are expected to boost the telehealth weight loss market, which has already grown rapidly. Hims & Hers reported that its GLP-1 prescribing business generated $225 million in revenue in 2025, up from $75 million in 2024 [6]. Ro's weight loss division grew by 180% over the same period.
These companies operate by connecting patients with licensed prescribers in their state, handling insurance verification or cash-pay billing, and coordinating medication delivery. The removal of in-person visit requirements reduces friction in the patient onboarding process and lowers costs for both the company and the patient.
Not everyone views this growth positively. The American Medical Association has expressed concern about what it calls "prescription mill" practices, where telehealth platforms incentivize high-volume prescribing without adequate patient evaluation. An AMA report published in January 2026 documented cases where telehealth encounters lasted less than five minutes before a GLP-1 prescription was issued [7].
What Patients Should Look For
Patients considering a telehealth provider for GLP-1 medication should evaluate several factors.
Verify that the prescribing clinician is licensed in your state and, ideally, board-certified in obesity medicine, endocrinology, or internal medicine. A legitimate telehealth provider will conduct a thorough medical history, review your medications for interactions, order or review lab work, and discuss realistic expectations, side effects, and the importance of lifestyle modifications alongside medication.
Be cautious of providers that guarantee a prescription before the visit, offer semaglutide or tirzepatide at prices significantly below market rate (which may indicate compounded products), do not ask about your medical history or current medications, or promise specific weight loss results.
Dr. Fitch recommended that patients ask their telehealth provider three questions: "What is your training in obesity medicine? What monitoring will you do during my treatment? And what happens if I have a side effect or medical concern between visits?" The answers to these questions can help distinguish between quality telehealth care and a prescription mill.
Other States Watching
Legislative staff in at least seven additional states, including New York, Illinois, Georgia, Ohio, Michigan, Virginia, and Arizona, are reviewing the California, Texas, and Florida models, according to the National Conference of State Legislatures. Several of these states have telehealth prescribing bills pending for the 2026 legislative session.
The federal government is also weighing in. The DEA's pandemic-era telehealth prescribing flexibilities are set to expire in December 2026, and Congress is debating whether to make them permanent. While GLP-1 medications are not DEA-controlled, the broader telehealth regulatory environment affects how platforms operate and how states draft their own rules.
Sources
- IQVIA. "Telehealth Prescribing Trends in Anti-Obesity Medications." February 2026.
- Medical Board of California. "Updated Telehealth Prescribing Guidelines." February 2026.
- Texas Legislature. "HB 2847: Telehealth Prescribing for Anti-Obesity Medications." 2026.
- Florida Board of Medicine. "Rule 64B8-9.0141: Telehealth Standards for Chronic Disease Medications." February 2026.
- American Board of Obesity Medicine. "Certification Statistics." 2026.
- Hims & Hers Health. "Q4 2025 Earnings Report." February 2026.
- American Medical Association. "Telehealth Prescribing Quality Review: Anti-Obesity Medications." January 2026.